Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy

Clinical Genitourinary Cancer

Volumn 9, Issue 1, 2011, Pages 27-30

  Galsky, Matthew D ^a   Seng, Sonia ^a   Camacho, Luis H ^b   Chiorean, Elena G ^c   Mulkerin, Daniel ^d   Hong, David S ^e   Oh, William K ^a   Bajorin, Dean F ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Oncology Consultants   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bladder cancer; Chemotherapy; chemotherapy; Metastatic; Platinum; Satraplatin; Urothelial cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; SATRAPLATIN;

ABDOMINAL PAIN; ADENOCARCINOMA; ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISEASE COURSE; DYSPNEA; FATIGUE; FEMALE; FEVER; HEMOPTYSIS; HUMAN; HYPERCALCEMIA; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LUNG EMBOLISM; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT CANCER; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 80052989951     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2011.05.003     Document Type: Article

References (17)

1. P.J. Loehrer Sr, L.H. Einhorn, and P.J. Elson A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 10 1992 1066 1073
2. H. von der Maase, S.W. Hansen, and J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077
3. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase IIresults of EORTC study 30986. 2009; 27:5634-9.
4. L.R. Kelland, G. Abel, and M.J. McKeage Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug Cancer Res 53 1993 2581 2586 (Pubitemid 23168026)
5. P.R. Twentyman, K.A. Wright, and P. Mistry Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin Cancer Res 52 1992 5674 5680
6. K.J. Mellish, C.F. Barnard, and B.A. Murrer DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines Int J Cancer 62 1995 717 723
7. G. Samimi, and S.B. Howell Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters Cancer Chemother Pharmacol 57 2006 781 788
8. H. Choy, C. Park, and M. Yao Current status and future prospects for satraplatin, an oral platinum analogue Clin Cancer Res 14 2008 1633 1638 (Pubitemid 351469447)
9. A. Dash, M.D. Galsky, and A.J. Vickers Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder Cancer 107 2006 506 513 (Pubitemid 44107210)
10. D.S. Hong, M. Galsky, and E. Chiorean Phase I study of the effects of renal impairment on the pharmacokinetic (PK) and safety of satraplatin in patients (Pts) with refractory non-hematologic cancer J Clin Oncol 24 suppl 2006 2044
11. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
12. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Institute 92 2000 205 216
13. C.N. Sternberg, D.P. Petrylak, and O. Sartor Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial J Clin Oncol 27 2009 5431 5438
14. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10 (Pubitemid 19099520)
15. M.D. Galsky, S. Mironov, and A. Iasonos Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma Invest New Drugs 25 2007 265 270 (Pubitemid 46774696)
16. A. Manunta, S. Vincendeau, and G. Kiriakou Non-transitional cell bladder carcinomas BJU Int 95 2005 497 502 (Pubitemid 40311458)
17. D.J. Stewart, and R. Kurzrock Cancer: the road to Amiens J Clin Oncol 27 2009 328 333